Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial
(FiPAKI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI). This study will explore whether finerenone can mitigate the risk of transitioning to chronic kidney disease following a moderate to severe AKI. Participants will be randomly assigned to receive either finerenone or a placebo, once daily for up to 45 days, in addition to their standard care. The study will monitor for side effects such as serum potassium levels and blood pressure, and will assess whether the drug helps prevent AKI from progressing to chronic kidney disease. This is a pilot feasibility study involving approximately 72 participants across 4-5 sites in Quebec and Ontario.
Who Is on the Research Team?
Jean-Maxime Côté, MD, MSc., FRCPC
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Are You a Good Fit for This Trial?
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Finerenone, 10mg, oral, once daily, for up to 45 days
Matching placebo, oral, once daily, for up to 45 days
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jean-Maxime Côté
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.